{"id":816969,"date":"2025-02-24T16:11:19","date_gmt":"2025-02-24T21:11:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/"},"modified":"2025-02-24T16:11:19","modified_gmt":"2025-02-24T21:11:19","slug":"mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/","title":{"rendered":"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Feb.  24, 2025  (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.<\/p>\n<p align=\"justify\">To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors &amp; Media section of the Mersana website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gero3A_KKqOpInHKT8uZLf3s_oSbYa7OQi4oOlqSyvUOsqEbk0Mz4-iJsExW1u20Fg_yosoHZZMhB5DLOjbbSYQb2_RG6rRXZOhIaCLWS0NpQNERoxhsh7W4kkrIoc6TiHO5-3_QnW1FmCD8_9eSU9z7Gc-X6D3MA9StyWPCFdjE1hYEEjSXSjCU-gI-d0tbM5crzrDCVpEuXFK4QiJIM_JeUfDsJ8uCy7vT8wqtPA=\" rel=\"nofollow\" target=\"_blank\">www.mersana.com<\/a>, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Mersana Therapeutics<\/strong><br \/>\n        <br \/>Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the \u201cInvestors &amp; Media\u201d section of its website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gero3A_KKqOpInHKT8uZEUAzPeP2FysSrqKLZE7giGoytNSxoKce7zVXF9cvUeOM7xnLze_dnXVjquuYSVEfw==\" rel=\"nofollow\" target=\"_blank\">www.mersana.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Jason Fredette <br \/>617-498-0020<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s2s_WOv6AnjGKtvu2BIoZJzo-JFwojdH6BC4FpasZfkXNmCCgC_QMT0WF_1Iei3QGRBjbD1uKEGN2GxHwSKKlhcBv2gF1KV_qfgIbi4oGTZQkp_TTiT6yVqUOOpTpGLL\" rel=\"nofollow\" target=\"_blank\">jason.fredette@mersana.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjY3YWQ3ZjItYjdkZS00YzQ2LTljYTItOWMyM2QwZGZiYzhkLTEwOTU2MDI=\/tiny\/Mersana-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors &amp; Media section of the Mersana website at\u00a0www.mersana.com, and a replay of the webcast will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816969","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors &amp; Media section of the Mersana website at\u00a0www.mersana.com, and a replay of the webcast will &hellip; Continue reading &quot;Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T21:11:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025\",\"datePublished\":\"2025-02-24T21:11:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/\",\"name\":\"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=\",\"datePublished\":\"2025-02-24T21:11:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/","og_locale":"en_US","og_type":"article","og_title":"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors &amp; Media section of the Mersana website at\u00a0www.mersana.com, and a replay of the webcast will &hellip; Continue reading \"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T21:11:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025","datePublished":"2025-02-24T21:11:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/"},"wordCount":270,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/","name":"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=","datePublished":"2025-02-24T21:11:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzYwMCM2NzYxMDAyIzIwODQwMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-fourth-quarter-and-year-end-2024-conference-call-on-march-3-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816969"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816969\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}